Myovant Sciences Ltd. (MYOV)
NYSE: MYOV
· Real-Time Price · USD
26.98
-0.01 (-0.04%)
At close: Mar 09, 2023, 10:01 PM
Myovant Sciences Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Revenue | 379.11M | 333.32M | 306.4M | 230.97M | 198.01M | 144.95M | 67.05M | 59.32M | 34.71M | 33.33M | 33.33M |
Cost of Revenue | 102.26M | 84.36M | 68.19M | 51.55M | 35.77M | 19.45M | 8.26M | 1.97M | n/a | n/a | n/a |
Gross Profit | 276.85M | 248.96M | 238.21M | 179.42M | 162.24M | 125.5M | 58.79M | 57.35M | 34.71M | 33.33M | 33.33M |
Operating Income | -146.91M | -154.75M | -139.38M | -187.35M | -212.36M | -230.93M | -284.43M | -260.78M | 26.91M | 27.16M | 31.59M |
Interest Income | 3.23M | 1.71M | 792K | 384K | 281K | 243K | 181K | 211K | 425K | 990K | 1.89M |
Pretax Income | -162.3M | -169.03M | -153.26M | -200.93M | -226.05M | -237.9M | -283.36M | -254.8M | -239.24M | -249.65M | -252.82M |
Net Income | -183.77M | -189.59M | -165.56M | -205.98M | -228.06M | -238.46M | -283.93M | -255.13M | -238.68M | -250.44M | -253.94M |
Selling & General & Admin | 316.92M | 302.66M | 277.18M | 259.36M | 270.15M | 247.27M | 219.81M | 181.42M | 125.82M | 105.72M | 91M |
Research & Development | 106.84M | 101.05M | 100.41M | 107.4M | 104.44M | 109.17M | 123.41M | 136.71M | 156.87M | 175.35M | 185.63M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 470K | 1.04M | 916K |
Operating Expenses | 423.76M | 403.71M | 377.6M | 366.77M | 374.59M | 356.44M | 343.21M | 318.14M | 282.69M | 281.06M | 276.63M |
Interest Expense | 18.62M | 15.98M | 14.67M | 13.97M | 13.97M | 13.1M | 11.72M | 10.4M | 8.33M | 9.38M | 11.05M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 526.02M | 488.07M | 445.79M | 418.32M | 410.37M | 375.88M | 351.47M | 320.1M | 282.69M | 281.06M | 276.63M |
Income Tax Expense | 21.47M | 20.56M | 12.3M | 5.05M | 2.01M | 560K | 575K | 336K | -554K | 791K | 1.12M |
Shares Outstanding (Basic) | 96.86M | 96.21M | 95.39M | 94.4M | 93.47M | 92.36M | 91.64M | 91.02M | 90.1M | 89.74M | 89.3M |
Shares Outstanding (Diluted) | 96.86M | 96.21M | 95.39M | 94.4M | 93.47M | 92.36M | 91.64M | 91.02M | 90.1M | 89.74M | 89.3M |
EPS (Basic) | -1.91 | -2 | -1.76 | -2.21 | -2.47 | -2.61 | -3.13 | -2.83 | -2.67 | -2.81 | -2.85 |
EPS (Diluted) | -1.91 | -2 | -1.76 | -2.21 | -2.47 | -2.61 | -3.13 | -2.83 | -2.67 | -2.81 | -2.85 |
EBITDA | -140.43M | -149.9M | -135.45M | -183.89M | -209.07M | -228.5M | -282.9M | -260.06M | -246.73M | -246.6M | -238.13M |
EBIT | -143.6M | -152.9M | -138.45M | -186.82M | -212.01M | -224.8M | -271.64M | -244.4M | -230.91M | -237.21M | -235.87M |
Depreciation & Amortization | 3.25M | 3.14M | 3.14M | 3.07M | 3M | 2.87M | 2.65M | 2.48M | 2.32M | 2.19M | 1.96M |